ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?

Lynparza may be the most popular PARP inhibitor, but a use restriction in ovarian cancer has been a thorn in AstraZeneca’s side. Now, the British pharma is bringing on its immunotherapy Imfinzi in the hope to remove that thorn, even though the path to market may be thorny.